These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 18235421)

  • 1. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
    Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
    Gulyás B; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
    Coenen HH; Elsinga PH; Iwata R; Kilbourn MR; Pillai MR; Rajan MG; Wagner HN; Zaknun JJ
    Nucl Med Biol; 2010 Oct; 37(7):727-40. PubMed ID: 20870148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging (PET) of brain tumors.
    Basu S; Alavi A
    Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorinated tracers for imaging cancer with positron emission tomography.
    Couturier O; Luxen A; Chatal JF; Vuillez JP; Rigo P; Hustinx R
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1182-206. PubMed ID: 15241631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET tracers in musculoskeletal disease beyond FDG.
    Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
    Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
    Fukuda H; Kubota K; Matsuzawa T
    Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging Cancer Metabolism with Positron Emission Tomography (PET).
    Witney TH; Lewis DY
    Methods Mol Biol; 2019; 1928():29-44. PubMed ID: 30725448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography in oncology: the most sophisticated imaging technology.
    Lacić M; Maisey MN; Kusić Z
    Acta Med Croatica; 1997; 51(1):1-9. PubMed ID: 9115096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non FDG PET.
    Nanni C; Fantini L; Nicolini S; Fanti S
    Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
    Shiue CY; Welch MJ
    Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of
    Ayubcha C; Hosoya H; Seraj SM; Zadeh MZ; Werner T; Alavi A
    Hell J Nucl Med; 2019; 22(1):4-5. PubMed ID: 30843002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New functional imaging technique "positron emission tomography"].
    Tamaki N
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):101-4. PubMed ID: 9612703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.
    Hara T; Bansal A; DeGrado TR
    Nucl Med Biol; 2006 Nov; 33(8):977-84. PubMed ID: 17127170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
    Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
    Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
    Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.